{"id":"cggv:d1ea2623-463f-40f1-befb-5dfde7abc784v1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:d1ea2623-463f-40f1-befb-5dfde7abc784_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10072","date":"2021-07-26T18:39:19.943Z","role":"Approver"},{"id":"cggv:d1ea2623-463f-40f1-befb-5dfde7abc784_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10072","date":"2021-07-26T18:39:30.252Z","role":"Publisher"}],"evidence":[{"id":"cggv:d1ea2623-463f-40f1-befb-5dfde7abc784_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:d1ea2623-463f-40f1-befb-5dfde7abc784_seg_el","type":"EvidenceLine","specifiedBy":"GeneValiditySegregationEvidencCriteria","strengthScore":3},{"id":"cggv:d1ea2623-463f-40f1-befb-5dfde7abc784_ad_null_el","type":"EvidenceLine","evidence":[{"id":"cggv:b0b7b223-8da6-4550-8291-9dee22cb1805_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:b9efff28-1fe6-4cbd-9081-ca98b6487299","type":"Proband","sex":"Female","variant":{"id":"cggv:b0b7b223-8da6-4550-8291-9dee22cb1805_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:8f71d909-2e29-4e43-ae5c-682a4f8cbeb0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004385.5(VCAN):c.4004-1G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA344474"}},"paternityMaternityConfirmed":"none","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/22739342","type":"dc:BibliographicResource","dc:abstract":"Wagner syndrome (WS) is an autosomal dominant vitreoretinopathy affecting various ocular features and is caused by mutations in the canonical splice sites of the VCAN gene, which encodes the large chondroitin sulfate proteoglycan, versican. We report the identification of novel splice acceptor and donor-site mutations (c.4004-1G>C and c.9265+2T>A) in two large WS families from France and the United Kingdom. To characterize their pathogenic mechanisms we performed qRT-PCR experiments on RNA from patient-derived tissues (venous blood and skin fibroblasts). We also analyzed RNA from the original Swiss family reported by Wagner (who has the previously reported c.9265+1G>A mutation). All three mutations resulted in a quantitative increase of transcript variants lacking exons 7 and/or 8. However, the magnitude of the increase varied between tissues and mutations. We discuss altered balance of VCAN splice variants in combination with reduction in glycosaminoglycan protein modifications as possible pathogenic mechanisms.","dc:creator":"Kloeckener-Gruissem B","dc:date":"2013","dc:title":"Novel VCAN mutations and evidence for unbalanced alternative splicing in the pathogenesis of Wagner syndrome."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/22739342","rdfs:label":"III-13"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5,"dc:description":"Absent in gnomAD, splicing alteration confirmed in patient fibroblast cells."},{"id":"cggv:ef1baac4-4970-4e41-a6e2-a2e96db466ed_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:b3b2d45e-7aa7-4092-b454-849754fc3e7b","type":"Proband","sex":"Female","variant":{"id":"cggv:ef1baac4-4970-4e41-a6e2-a2e96db466ed_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:7b4bfbf8-e2a1-461c-8d5f-8b3e640f1350","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004385.5(VCAN):c.9265+2T>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA344473"}},"paternityMaternityConfirmed":"none","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22739342"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/22739342","rdfs:label":"IV-3"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5,"dc:description":"Absent in gnomAD, splicing alteration confirmed in patient fibroblast cells."},{"id":"cggv:b5030495-ebc2-46a1-8e69-daaeb8a439da_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:6eb538ea-7bb7-4b7a-9f80-12a6add13ce5","type":"Proband","detectionMethod":"Linkage analysis was performed using custom markers on chromosome 5 and 12, previously linked regions to Wagner syndromes (5q13-q14; WGN1 locus and 12q12; COL2A1 gene). A maximum LOD of 3.5 was observed for 5q13-q14 and 12q12 locus was excluded. Sanger sequencing of 10 candidate genes in 5q13-q14 identified a canonical splicing variant c.4004-2A>G in the 11 affected individuals but not in 2 un-affected individuals.","firstTestingMethod":"Linkage analysis","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:b5030495-ebc2-46a1-8e69-daaeb8a439da_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:9c1ab1e2-9cbb-4925-82d2-0a4f5091cedb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004385.5(VCAN):c.4004-2A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA341462"}},"paternityMaternityConfirmed":"none","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/16043844","type":"dc:BibliographicResource","dc:abstract":"To investigate the genetic basis and clinical variability of Wagner syndrome, a rare, dominantly inherited vitreoretinopathy.","dc:creator":"Miyamoto T","dc:date":"2005","dc:title":"Identification of a novel splice site mutation of the CSPG2 gene in a Japanese family with Wagner syndrome."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/16043844","rdfs:label":"IV-1"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5,"dc:description":"Absent in gnomAD, splicing alteration confirmed in patient lymphoblastoid cells."},{"id":"cggv:3a8e3a8c-6530-4c80-9f99-8aa8f1c1612a_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:8105dcf2-3d7c-467e-849a-2012d1bd3faa","type":"Proband","detectionMethod":"The linkage analysis of this family was described by Brown et al. in  https://pubmed.ncbi.nlm.nih.gov/7748141/, which identified a highly significant linkage (lod score >5.0) between the disease and 10 markers of the chromosome 5q13-q14 region.  Kloeckener-Gruissem et al then used Sanger sequencing to analyze two of the candidate genes in this region, VCAN (aka CSPG2) and EDIL3. A rare variant c.9265+1G>A  in the VCAN gene was found to be segregated with the disease in 21 affected and 26 unaffected individuals.","firstTestingMethod":"Linkage analysis","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:3a8e3a8c-6530-4c80-9f99-8aa8f1c1612a_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:3c9153ca-8aad-4ae0-87a1-f31bd55cf3c5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004385.5(VCAN):c.9265+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA342038"}},"paternityMaternityConfirmed":"none","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/16636652","type":"dc:BibliographicResource","dc:abstract":"The aim of the present study was to determine the genetic defect in Wagner syndrome, a rare disorder belonging to the group of hereditary vitreoretinal degenerations. This disease has been genetically mapped to chromosome 5q14.3.","dc:creator":"Kloeckener-Gruissem B","dc:date":"2006","dc:title":"Identification of the genetic defect in the original Wagner syndrome family."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/16636652","rdfs:label":"49"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5,"dc:description":"Variant absent in gnomAD 2.1, Splicing alteration confirmed in patient blood RNA."},{"id":"cggv:c7098b5b-021c-41f1-9a41-b34872477f01_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:f0e9a1c5-6a40-4477-898e-aaf5ddd65329","type":"Proband","sex":"Female","variant":{"id":"cggv:c7098b5b-021c-41f1-9a41-b34872477f01_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:6c4fa5dc-fbcd-4640-be9b-e050e699e95b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004385.5(VCAN):c.4004-2A>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA344472"}},"paternityMaternityConfirmed":"none","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/21738396","type":"dc:BibliographicResource","dc:abstract":"To detail the highly variable ocular phenotypes of a French family affected with an autosomal dominantly inherited vitreoretinopathy and to identify the disease gene.","dc:creator":"BrÃ©zin AP","dc:date":"2011","dc:title":"A new VCAN/versican splice acceptor site mutation in a French Wagner family associated with vascular and inflammatory ocular features."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21738396","rdfs:label":"V.5"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5,"dc:description":"Absent in gnomAD, splicing alteration shown in patient lymphoblast cells."},{"id":"cggv:ed33c4af-d602-4346-933d-b4b5851fe414_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:e0e3edff-a7a8-4b15-961a-b1553493f106","type":"Proband","detectionMethod":"Linkage analysis performed using STR markers on the Wagner disease/ERVR locus on chromosome 5. Sanger was performed for the exons and exon-intron junctions for the genes in the minimum region, ie, VCAN and XRCC4.","firstTestingMethod":"Linkage analysis","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:ed33c4af-d602-4346-933d-b4b5851fe414_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:be9448a2-ea1a-412f-a6ec-ab09fedb8f16","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004385.5(VCAN):c.4004-5T>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA342037"}},"paternityMaternityConfirmed":"none","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/16877430","type":"dc:BibliographicResource","dc:abstract":"Linkage intervals for erosive vitreoretinopathy (ERVR) and Wagner disease previously were found to overlap at 5q14.3. In a Japanese family with Wagner disease, a CSPG2/Versican splice site mutation (c.4004-2A-->G) was recently reported that resulted in a 39-nucleotide exon 8 in-frame deletion. We investigated whether CSPG2/Versican was mutated in six Dutch families and one Chinese family with Wagner disease and in a family with ERVR.","dc:creator":"Mukhopadhyay A","dc:date":"2006","dc:title":"Erosive vitreoretinopathy and wagner disease are caused by intronic mutations in CSPG2/Versican that result in an imbalance of splice variants."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/16877430","rdfs:label":"023A"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5,"dc:description":"Absent in gnomAD, found to cause increased V2 & V3 isoform expression in patient blood RNA (Table 4). "}],"specifiedBy":"GeneValidityOverallAutosomalDominantNullVariantEvidenceCriteria","strengthScore":9},{"id":"cggv:d1ea2623-463f-40f1-befb-5dfde7abc784_ad_dn_el","type":"EvidenceLine","evidence":[{"id":"cggv:e3f4c76d-2ad1-42b9-ad19-d5cbd226e527_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:05eeded4-f036-42ea-95ca-e211ef1ac92f","type":"Proband","phenotypeFreeText":"Retinal detachment, cataract, optically empty vitreous with a circumferential avascular preretinal membrane, ectopic macula responsible for exotropia (pseudostrabismus), mild temporal dragging of retinal vessels. Kinetic perimetry showed a constricted peripheral isopter, and full-field electroretinography revealed mild cone-rod dysfunction.","sex":"Male","variant":{"id":"cggv:e3f4c76d-2ad1-42b9-ad19-d5cbd226e527_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:3c9153ca-8aad-4ae0-87a1-f31bd55cf3c5"},"paternityMaternityConfirmed":"none","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/23571384","type":"dc:BibliographicResource","dc:creator":"Rothschild PR","dc:date":"2013","dc:title":"De novo splice mutation in the versican gene in a family with Wagner syndrome."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23571384","rdfs:label":"II-1"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2,"dc:description":"Not detected in blood DNA of the proband's parents, and paternity was confirmed with highly polymorphic markers. Same variant reported in PMID: 16636652 and other publications."}],"specifiedBy":"GeneValidityOverallAutosomalDominantDeNovoVariantEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"cggv:d1ea2623-463f-40f1-befb-5dfde7abc784_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:d1ea2623-463f-40f1-befb-5dfde7abc784_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:535f06d4-2416-4a24-9e23-bbb0d55049bb","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:b9786cc8-f56d-4584-a571-1668d61b6450","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"RT-qPCR showing four VCAN isoforms using cell culture of human trabecular meshwork, human ciliary muscle and its culture.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/16110303","type":"dc:BibliographicResource","dc:abstract":"Versican, chondroitin sulfate glycoprotein 2, is thought to play a role in regulating aqueous humor outflow and intraocular pressure via the human trabecular meshwork (HTM) of the eye. This protein was upregulated in HTM cells when they were treated with TGF-beta. There are four splice variant forms of versican (V0-V3) with different numbers of glycoaminoglycan (GAG) attachment domains. In this study, we investigated the various isoforms of versican from ocular tissues and cultured cells.","dc:creator":"Zhao X","dc:date":"2005","dc:title":"Versican splice variants in human trabecular meshwork and ciliary muscle."},"rdfs:label":"RT-qPCR"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"cggv:3afb89f5-9fe9-4d1f-9ada-9dcecfb1009f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Inconclusive","evidence":[{"id":"cggv:6d5ee0ec-600d-42ae-86bb-43da86e38f1e","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"Alpha & beta versican expressed in rat retina starting at embryonic day 13. By postnatal day 0 (P0), beta-versican staining  is  largely  confined  to  the  inner  plexiform  layer, whereas alpha-versican is also apparent in the neuroblast layer. At P9, versican staining is most intense in the inner and outer plexiform and ganglion cell layers, accompanied by diffuse staining in the inner and outer nuclear layers.  In adult rat, alpha-versican immunoreactivity is seen in the retina and optic nerve,  whereas beta-versican has essentially disappeared from the adult retina and is present only in the laminar beams of the optic nerve.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/15336497","type":"dc:BibliographicResource","dc:abstract":"We have used a monoclonal antibody to neurocan and specific polyclonal antibodies to the non-homologous glycosaminoglycan attachment regions of aggrecan and mRNA splice variants of versican to compare the localization and developmental changes of these structurally related hyaluronan-binding chondroitin sulfate proteoglycans in the rat retina and optic nerve. Staining for aggrecan and versican was first seen at embryonic day 16 in the optic nerve and retina, whereas neurocan was not detected in the embryonic eye. At postnatal day 0 (P0), beta-versican staining is largely confined to the inner plexiform layer whereas alpha-versican is also apparent in the neuroblastic layer. Both aggrecan and, much more weakly, neurocan immunoreactivity is present throughout the neonatal retina. At P9, aggrecan and versican immunoreactivity is most intense in the inner and outer plexiform and ganglion cell layers, accompanied by diffuse staining in the inner and outer nuclear layers. Aggrecan and alpha-versican are also present throughout the optic nerve and disk, whereas beta-versican and neurocan are confined to the laminar beams of the optic nerve. Between P0 and P9 there is a marked increase in beta-versican expression in the inner and outer nuclear layers and in the outer plexiform layer, whereas there is only weak staining of neurocan in the inner plexiform and ganglion cell layers of P9 retina. By 1 month postnatal the staining pattern of the fully differentiated retinal layers is essentially identical to that seen in the adult, where there is strong aggrecan and alpha-versican immunoreactivity in the retina and optic nerve, whereas beta-versican has essentially disappeared from the adult retina and, similarly to neurocan, is present only in the laminar beams of the optic nerve. The marked decrease of beta-versican in the retina is consistent with >90% decrease in its concentration in brain during postnatal development, suggesting that the developmental time-course for these proteoglycans in retina parallels that seen in other areas of the central nervous system.","dc:creator":"Popp S","dc:date":"2004","dc:title":"Developmental changes of aggrecan, versican and neurocan in the retina and optic nerve."},"rdfs:label":"IHC staining of versican in rat retina"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0.5}],"evidenceStrength":"Definitive","sequence":3149,"specifiedBy":"GeneValidityCriteria8","strengthScore":12.5,"subject":{"id":"cggv:4334150f-ebf0-43b2-98fc-8fa09d0b9b78","type":"GeneValidityProposition","disease":"obo:MONDO_0007740","gene":"hgnc:2464","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","dc:description":"Variants in VCAN have been reported in multiple families affected by autosomal dominant Wagner disease since 2005 (Miyamoto et al., PMID 16043844). At least six splicing variants in intron 7 (transcript NM_004385.5) have been reported in humans, often in large families segregating perfectly with the disease. More evidence including additional splicing variants in intron 7 and large deletions involving exon 8 is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. This gene-disease association is further supported by expression studies showing that VCAN is expressed in the eye. In summary, VCAN is definitively associated with autosomal dominant Wagner disease.","dc:isVersionOf":{"id":"cggv:d1ea2623-463f-40f1-befb-5dfde7abc784"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}